Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly.
Here are are a few highlights from this week:
- Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study (Lancet Oncol) - The interim analyses from the KEYNOTE-204 study confirmed significant improvement in PFS with pembrolizumab as compared to brentuximab vedotin in HL patients.
- A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells (Blood Adv) - BiTEs vs. CAR-T in the treatment of MM? This bispecific T-cell–engaging antibody shows similar anti-MM activity compared with BCMA CAR T cells but with more rapid in vivo kinetics.
- Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial (J Clin Oncol) - The risk-adapted administration of preemptive tocilizumab (anti-IL6 mAb) may decrease the expected incidence of grade 4 CRS following CAR-T treatment, without adversely impacting efficacy or safety.
- Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma (Blood) - Pembrolizumab, already approved for R/R HL, demonstrated both highly efficacy and safeness in patients with newly diagnosed cHL, including those with bulky disease.
You can access our complete resource library of scientific publications here.
Last Updated on Thursday 25 March 2021.